Dr. Peter Bryan has over 20 years of pharmaceutical industry experience – primarily in the area of regulated DMPK bioanalysis (small molecules, metabolites, biomarkers, peptides and biotherapeutics). Presently, he provides consulting services to the pharmaceutical industry. Dr. Bryan has extensive experience developing and managing bioanalytical groups supporting regulated non-clinical and clinical sample analysis. He also has extensive experience in method development, validation, sample analysis, project management and LIMS. His responsibilities have included monitoring, auditing and qualifying bioanalytical CROs, and as a study monitor for numerous non-clinical and clinical studies representing multiple project teams. Dr. Bryan is a leader and subject matter expert in the areas of non-clinical dose formulation analysis (NCDFA), microsampling, and dried blood spot (DBS) analysis, where he has co-authored of numerous white papers in these areas, including a white paper regarding the use of dried-blood spot sample collection and analysis in clinical studies. Additionally, Dr. Bryan has co-authored of a book chapter covering bioanalytical method development, validation and sample analysis. He was elected to the AAPS Leadership in 2011 for a five-year leadership progression (2015 APQ Section Chair). Dr. Bryan has a B.S. in Biology from the University of the South (Sewanee), a B.S. in Chemistry from Samford University, and a Ph.D. in Medicinal Chemistry from the University of Georgia, College of Pharmacy.
“We cannot limit our practices to the way things have always been done in the past”. “Let’s go invent tomorrow instead of worrying about what happened yesterday.” Steve Jobs